Phase 1
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
First patient enrolled at The University of Kansas Cancer Center in expansion cohort study characterizing the safety, pharmacokinetics and pharmacodynamics of fosciclopirox in bladder cancer patients
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability of warfarin or clonazepam, two widely used drugs with narrow therapeutic index.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
PRESS RELEASES